Viatris (VTRS) Net Cash Flow Growth (3y) (2022 - 2026)

Viatris (VTRS) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (3y) (Qtr)
1 Haleon 88.74 Bn 86.88 Bn - -
2 Teva Pharmaceutical Industries 35.87 Bn 32.13 Bn 1.97 Bn 32.03%
3 Zoetis 32.28 Bn 30.34 Bn 1.62 Bn 28.99%
4 Takeda Pharmaceutical 27.51 Bn 23.45 Bn 4.39 Bn 37.89%
5 United Therapeutics 23.14 Bn 20.98 Bn 648.10 Mn -49.94%
6 RedHill Biopharma 20.53 Bn 20.53 Bn - -
7 Viatris 20.25 Bn 18.44 Bn 1.16 Bn 37.74%
8 Neurocrine Biosciences 17.89 Bn 16.57 Bn 800.70 Mn -41.05%
9 Elanco Animal Health 12.64 Bn 12.21 Bn 785.00 Mn -62.71%
10 Vireo Growth 10.52 Bn 10.37 Bn 59.30 Mn 73.08%

Historic Data

Download Data
DateValue
Mar 31, 2026 37.74%
Dec 31, 2025 -14.86%
Sep 30, 2025 349.65%
Jun 30, 2025 -48.84%
Mar 31, 2025 -62.13%
Dec 31, 2024 -190.33%
Sep 30, 2024 118.49%
Jun 30, 2024 13.34%
Mar 31, 2024 63.37%
Dec 31, 2023 -59.14%
Mar 31, 2023 -101.97%
Dec 31, 2022 76.06%